World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
53678
World Ranking
11505
National Ranking
5898

Overview

Adil Daud is affiliated with the University of California, San Francisco in the United States. Their research primarily spans the field of Medicine, with a concentrated focus on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, as well as Cancer Research.

The scientist's work covers multiple topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Immune Cell Function and Interaction
  • Cutaneous Melanoma Detection and Management
  • T-cell and B-cell Immunology

Adil Daud has published extensively in several venues, notably:

  • Cancer (31 publications)
  • Journal of Clinical Oncology (18 publications)
  • Regular and Young Investigator Award Abstracts (15 publications)
  • Cancer Research (8 publications)
  • Annals of Oncology (4 publications)

Notable recent publications include:

  • "Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis," 2020, Science Immunology
  • "Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer," 2020, Nature Communications
  • "Discovering dominant tumor immune archetypes in a pan-cancer census," 2021, Cell
  • "Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma," 2020, Clinical Cancer Research
  • "Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma," 2021, Journal for ImmunoTherapy of Cancer

Frequent collaborators of Adil Daud include:

  • Patrick K. Ha
  • Christina Wu
  • Chunxue Bai
  • Joseph Bauer
  • Eric Bernicker

Best Publications

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

    Miranda L. Broz;Mikhail Binnewies;Bijan Boldajipour;Amanda E. Nelson

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.

    Kevin C. Barry;Joy Hsu;Miranda L. Broz;Francisco J. Cueto;Francisco J. Cueto;Francisco J. Cueto

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

    O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

  • Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

    Christopher S. Garris;Sean P. Arlauckas;Rainer H. Kohler;Marcel P. Trefny

  • Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

    Adil I. Daud;Ronald C. DeConti;Stephanie Andrews;Patricia Urbas

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

    F. Stephen Hodi;Wen Jen Hwu;Richard Kefford;Jeffrey S. Weber

  • Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos

  • Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Adil I. Daud;Jedd D. Wolchok;Caroline Robert;Wen Jen Hwu

  • A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

    Carol Aghajanian;Steven Soignet;Don S. Dizon;Christine S. Pien

  • The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

    Adam I Riker;Steven A Enkemann;Oystein Fodstad;Suhu Liu

Frequent Co-Authors

Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Caroline Robert
Caroline Robert University of Paris-Saclay
Richard F. Kefford
Richard F. Kefford Macquarie University
Georgina V. Long
Georgina V. Long University of Sydney
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Rene Gonzalez
Rene Gonzalez University of Colorado Anschutz Medical Campus
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Amita Patnaik
Amita Patnaik University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't have to be limited to becoming a doctor. There are many alternative pathways and online degrees that offer rewarding roles in healthcare. For those interested in entering the workforce quickly, fast LPN program options can prepare you for practical nursing in as little as a year. If you already have a nursing background and want to specialize, the fastest pmhnp program options are streamlined to help you become a Psychiatric Mental Health Nurse Practitioner efficiently.

For those drawn to healthcare leadership or administration, pursuing a bachelors in healthcare administration can open doors to essential non-clinical roles. Advancing your education further is possible and potentially affordable through a masters in healthcare administration cost overview, which details budget-friendly graduate programs. These online degrees not only offer flexibility, but also support diverse career options within the broader field of medicine.

Best Scientists Citing Adil Daud

Trending Scientists